Lewis Tanya
Insider CIK 1451038 · DMAC Director · KPTI EVP,Chief Reg.&Quality Officer · REPL Chief Dev.Op Off, Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| DMAC DiaMedica Therapeutics Inc | A Award deriv | 2026-06-01 | 2026-06-03 | 40,412 | — | $0 | 40,412 | SEC↗ |
| DMAC DiaMedica Therapeutics Inc | A Award deriv | 2025-06-01 | 2025-06-03 | 32,162 | — | $0 | 32,162 | SEC↗ |
| DMAC DiaMedica Therapeutics Inc | A Award deriv | 2024-06-01 | 2024-06-03 | 28,472 | — | $0 | 28,472 | SEC↗ |
| REPL Replimune Group, Inc. | S Sale | 2023-06-13 | 2023-06-15 | 817 | $23.45 | $19.2K | 135,293 | SEC↗ |
| REPL Replimune Group, Inc. | S Sale | 2023-06-13 | 2023-06-15 | 12,043 | $24.10 | $290.2K | 136,110 | SEC↗ |
| DMAC DiaMedica Therapeutics Inc | A Award deriv | 2023-06-01 | 2023-06-02 | 7,493 | — | $0 | 7,493 | SEC↗ |
| REPL Replimune Group, Inc. | S Sale | 2023-05-16 | 2023-05-18 | 12,207 | $18.05 | $220.3K | 148,153 | SEC↗ |
| REPL Replimune Group, Inc. | A Award deriv | 2023-04-01 | 2023-04-04 | 60,000 | — | $0 | 60,000 | SEC↗ |
| REPL Replimune Group, Inc. | A Award | 2023-04-01 | 2023-04-04 | 40,000 | — | $0 | 160,360 | SEC↗ |
| DMAC DiaMedica Therapeutics Inc | A Award deriv | 2023-03-01 | 2023-03-06 | 26,443 | — | $0 | 26,443 | SEC↗ |
| REPL Replimune Group, Inc. | S Sale | 2022-05-16 | 2022-05-18 | 5,473 | $14.59 | $79.9K | 120,360 | SEC↗ |
| REPL Replimune Group, Inc. | A Award deriv | 2022-04-01 | 2022-04-05 | 78,750 | — | $0 | 78,750 | SEC↗ |
| REPL Replimune Group, Inc. | A Award | 2022-04-01 | 2022-04-05 | 52,500 | — | $0 | 125,833 | SEC↗ |
| REPL Replimune Group, Inc. | A Award deriv | 2021-05-10 | 2021-05-11 | 110,000 | — | $0 | 110,000 | SEC↗ |
| REPL Replimune Group, Inc. | A Award | 2021-05-10 | 2021-05-11 | 73,333 | — | $0 | 73,333 | SEC↗ |
| REPL Replimune Group, Inc. | A Award deriv | 2021-04-01 | 2021-04-05 | 16,500 | — | $0 | 16,500 | SEC↗ |
| KPTI Karyopharm Therapeutics In | A Award deriv | 2021-02-25 | 2021-03-01 | 59,968 | — | $0 | 59,968 | SEC↗ |
| KPTI Karyopharm Therapeutics In | A Award | 2021-02-25 | 2021-03-01 | 22,013 | — | $0 | 45,401 | SEC↗ |
| KPTI Karyopharm Therapeutics In | S Sale | 2021-02-11 | 2021-02-17 | 2,046 | $15.52 | $31.8K | 4,143 | SEC↗ |
| KPTI Karyopharm Therapeutics In | M Exercise deriv | 2021-02-05 | 2021-02-09 | 5,650 | — | $0 | 16,950 | SEC↗ |
| KPTI Karyopharm Therapeutics In | M Exercise | 2021-02-05 | 2021-02-09 | 5,650 | — | $0 | 6,189 | SEC↗ |
| REPL Replimune Group, Inc. | A Award deriv | 2020-11-02 | 2020-11-03 | 33,000 | — | $0 | 33,000 | SEC↗ |
| KPTI Karyopharm Therapeutics In | S Sale | 2020-10-30 | 2020-11-04 | 226 | $15.58 | $3.5K | 539 | SEC↗ |
| KPTI Karyopharm Therapeutics In | M Exercise deriv | 2020-10-28 | 2020-11-04 | 765 | — | $0 | 2,295 | SEC↗ |
| KPTI Karyopharm Therapeutics In | M Exercise | 2020-10-28 | 2020-11-04 | 765 | — | $0 | 765 | SEC↗ |
| KPTI Karyopharm Therapeutics In | A Award deriv | 2020-02-05 | 2020-02-07 | 22,600 | — | $0 | 22,600 | SEC↗ |
| KPTI Karyopharm Therapeutics In | A Award deriv | 2020-02-05 | 2020-02-07 | 60,600 | — | $0 | 60,600 | SEC↗ |